Lilly Continues Positive Outlook For Migraine Treatment

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says a 12-month Phase 3 study of a migraine treatment has shown continued positive results. The pharmaceutical giant says the study for galcanezumab showed a "statistically significant reduction in the number of monthly migraine headache days" among patients.

Lilly says the treatment "demonstrated a positive safety and tolerability profile in patients with migraine, consistent with previous studies." Patients received two different doses and the company says there was "no clinically meaningful difference" in the rate of adverse effects between the dosages.

Lilly's previously-announced plans to submit a Biologics License Application to the U.S. Food and Drug Administration remain set for the second half of 2017. The company also plans to submit to other regulatory agencies throughout the world.

"These long-term results are significant for the millions of Americans with migraine. They reinforce the efficacy and safety profile of galcanezumab while supporting its potential use as a self-administered, monthly injection," said Christi Shaw, president of Lilly Bio-Medicines. "After more than two decades of research, Lilly is excited to submit galcanezumab to the FDA as a new potential treatment option that can provide more migraine-free days for people suffering with migraine."

Lilly is presenting the results of the study at the 18th Congress of the International Headache Society in Vancouver. The company also plans to submit the findings for publication in a peer-reviewed journal "in the coming year."

The announcement comes just one day after Lilly detailed plans for a global restructuring, affecting about 3,500 employees. The company said the move will allow it to invest in the next generation of new medicines.

The open office floor plan has become very popular over the past decade, and it really does encourage collaboration among employees. It's also taught people how to hide in the wide open by focusing in on their own space to hold onto some privacy and focus. Those who have worked in a busy office know that you adapt by...

Events

Most Popular Stories

The American Heart Association has recognized eight Indiana organizations on its Workplace Health Achievement Index. More than 800 companies throughout the country were assessed on the index, which evaluates the overall quality and comprehensiveness of a company's workplace health program.

President Donald Trump will Wednesday make a stop at the Indiana State Fairgrounds. Our partners at WTHR-TV report the president will speak to supporters about tax reform, just days after Vice President Mike Pence did the same during a visit to Anderson.

Two local economic development leaders in the state have been recognized nationally for their use of technology. The Digital 25 was compiled using responses to Community Systems 2017 Economic Development Technology Survey, which covered the importance of technology to respondents' jobs, how much time they spent using technology each week and what percentage of their budgets are dedicated to technology.

A manufacturer of aftermarket motorcycle performance parts has announced plans to halt operations at its Brownsburg facility. In a notice to the state, California-based Vance & Hines Performance LLC says the decision will result in the layoffs of 70 employees.

Alaska Airlines today begins nonstop daily service to San Francisco International Airport. The service is in addition to the airline's nonstop to Seattle, which began in May. When the service was first announced in March, Indy Airport Executive Director Mario Rodriguez said the move "sends a clear message about the value Alaska Airlines sees in Indianapolis," and called San Francisco a "crucial market that connects not only regions but continents."